top of page
GCS MAX BHBR Horse without Pattern.webp
Pattern Shadow.webp
The bar has been raised.png
GCS MAX

GET REWARDED

with the GCS-MAX loyalty program

GCS MAX Loyalty Card Web Image-2.webp

Terms & Conditions

The GCS-MAX loyalty program is exclusive to select outlets only and at the sole discretion of Kyron Vet Rx. The loyalty program can be cancelled with immediate effect and is subject to stock availability. Free stock is supplied in the form of GCS-MAX, in alignment with the customer’s product selection on the loyalty card. The completed loyalty cards must be submitted to the participating outlet as indicated on the front side of the loyalty card. Each purchase of GCS-MAX must have a date and signature from the participating outlet.  In order to qualify for the FREE PRODUCT, 6 proof of purchases must be completed and indicated on the GCS-MAX loyalty card.

GCS MAX JC Pouch.png
GCS MAX JC Tub.png
GCS MAX JCA Pouch.png
GCS MAX JCA Tub1.png
Nutritional aid.png
Hydrolysed collagen Type II.2.png
ASU Icon.2.png

NOW WITH

Chondroitin Sulphate Icon.2.png
Glucosamine Icon.2.png
MSM Icon.2.png

GCS MAX promotes the production, protection and restoration of joint cartilage in horses. It is a nutritional aid that has been developed for competing sport horses with a high workload and horses prone to joint issues.

GCS MAX Range
Chondroitin Sulphate Icon.3.png

CHONDROITIN SULPHATE
Chondroitin sulphate has been shown to promote active cartilage regeneration, inhibit
degenerative enzymes, reduce pain and inhibit subchondral bone resorption.

2,3,10

GLUCOSAMINE HYDROCHLORIDE
Glucosamine is an important precursor for proteoglycan production and has
been shown to prevent cartilage degeneration and subchondral bone resorption,
enhance chondrocyte proliferation and extracellular matrix production.      

2,3,11

Glucosamine Icon.3.png
Collagen Type II.png

HYDROLYSED COLLAGEN TYPE II
Hydrolysed collagen type II has been shown to accumulate in the articular cartilage
and stimulates the chondrocyte to produce type II collagen, restoring the architectural
integrity of the cartilage. It has also been shown to increase mobility and reduce pain.

3,8

AVOCADO/SOYABEAN UNSAPONIFIABLES (ASU)
ASU supplementation caused a significant reduction on the degree of macroscopic
cartilage erosion, synovial hemorrhage scores and intimal hyperplasia in the
synovial membrane. 

ASU.3.png

4

MSM.3.png

2,3

MSM
MSM acts as an antioxidant within the joint and reduces both joint and muscle pain
when given as a pre-treatment before strenuous endurance excercises.

7

Pattern Shadow_edited_edited.png
Ingredients

LAMENESS IN HORSES:

Lameness is the main cause of training days lost and failure to compete and is the primary reason for poor performance and early retirement
of competing horses.

1,12

Horse.webp
GCS MAX Joint Red Dot.png
GCS MAX Joint Red Dot.png
GCS MAX Joint Red Dot.png
GCS MAX Joint Red Dot.png
GCS MAX Joint Red Dot.png
GCS MAX Joint Red Dot.png
GCS MAX Joint Red Dot.png
GCS MAX Joint Red Dot.png
GCS MAX Joint Red Dot.png
GCS MAX Joint Red Dot.png
GCS MAX Joint Red Dot.png
GCS MAX Joint Red Dot.png
Skeleton.webp
Red Dots.webp
95%-Lameness_edited_edited.png
95%-Lameness_edited_edited.png
80%-Lameness_edited.png
80%-Lameness_edited.png
Lameness in Horses

Studies show that:

± 60% of lameness in horses are related to osteoarthritis and

4,12

up to 33% of horses assessed in hospital had visible intra-articular lesions related to osteoarthritis. 

Causes of Lameness
Detailer horse inner_edited.png

  • circulatory and nervous disorders;

  • shoeing;

  • nutritional deficiencies;

  • managemental and environmental factors;

  • and ageing.

  • Trauma to the joint;

  • conformation;

  • developmental defects;

  • infection;

  • metabolic disturbances;

Arthiritic Knee Joint.png

CAUSES OF LAMENESS AND ASSOCIATED OSTEOARTHRITIS IN HORSES:

1,12

All of the above can lead to changes in the joint and articular cartilage

1,12

OA diseased cartilage large.png

Broken collagen type II fibers

Diseased chondrocyte

Degraded extracellular matrix

In osteoarthritic cartilage the metabolism of chondrocytes get disturbed, causing the slowdown of production of extracellular matrix components and the decrease of essential building blocks of cartilage like hyaluronan
and proteoglycans.   

Joint inflammation causes destructive enzymes
to increase leading to the breakdown and
degeneration of the structure within the
cartilage. 

5,8

2

Image of diseased cartilage with degraded extracellular matrix

2

Osteoarthritis

Over time this breakdown causes the cartilage to thin and become brittle and uneven, giving way to:

2,3,5

Arthritic Cartilage.png

MACROSCOPIC LESIONS:

MACROSCOPIC LESIONS:

  • subchondral bone destruction;

  • formation of osteophytes or bone spurs;

  • meniscal lesions;

  • and fibrillation and erosion of the cartilage.

  • disorganization of the chondrocytes;

  • decrease of proteoglycans;

  • and synovial inflammation.

Healing is often  delayed as cartilage lacks both nerves and  blood vessels.

3

THE ROLE OF CHONDROPROTECTORS & DISEASE MODIFYING OA DRUGS

Compounds that either protect the articular cartilage during the course of OA or alter the course of the disease by modifying the biochemical cascades that contribute to OA.

9

Chondroprotectors like glucosamine, chondroitin sulphate and collagen hydrolysate are all basic components of the cartilage and synovial fluid, and have been shown to:

3

  • slow the progression of cartilage destruction;

  • help regenerate the joint structure;

  • reduce pain in the joint;

  • and increase mobility by providing protection.

Glucosamine and Chodroitin study.png
Hydrolysed collagen type II study.png
Chondroprotectors

GCS MAX Joint Care

GCS MAX Composition.png
GCS MAX JCA Tub1.png
GCS MAX JC Tub.png
GCS MAX JCA Pouch.png
GCS MAX JC Pouch.png
Composition

Directions for use

GCS MAX Directions for use.png
Directions for use
Contact

References:

1. Tank, D.P., Bhatt, R.H., Dodia, V.D., Vadalia, J.V. & Padaliya, N.R., 2020. Epidemiological status of lameness in horses: a retrospective study. International Journal of Current Microbiology and Applied Sciences,
9(9):681-687. doi: https://doi.org/10.20546/ijcmas.2020.909.086. 2. Neil, K.M., Caron, J.P. & Orth, M.W., 2005. The role of glucosamine and chondroitin sulfate in treatment for and prevention of osteoarthritis
in animals. Journal of the American Veterinary Medical Association, 226(7):1079-1088. 3. Jerosch, J., 2011. Effects of glucosamine and chondroitin sulfate on cartilage metabolism in OA: outlook on other nutrient
partners especially omega-3 fatty acids. International Journal of Rheumatology, 11. doi:10.1155/2011/969012. 4. McIlwraith, C.W., 2013. Oral joint supplements in the management of osteoarthritis. Clinical
Nutrition, 33:549-556. doi:10.1016/b978-0-7020-3422-0.00033-x. 5. Rebai, M.A., Sahnoun, N., Abdelhedi, O., Keskes, K., Char, S., Slimi, F., Frikha, R. & Keskes, H., 2020. Animal models of osteoarthritis:
characterization of model induced by mono-lodo-acetate injected in rabbits. Libyan Journal of Medicine, 15(1):1753943. doi:10.1080/19932820.2020.1753943. 6. Gupta, R.C., Canerdy, T.D., Skaggs, P., Stocker, A.,
Zyrkowski, G., Burke, R., Wegford, K., Goad, J.T., Rohde, K., Barnett, D., DeWees, W., Bagghi, M. & Bagghi, D., 2009. Therapeutic effects of undenatured type-II collagen (US-II) in comparison to glucosamine and
chondroitin in arthritic horses. Journal of veterinary pharmacology and therapeutics, 32:577-584. doi: 10.1111/j.1365-2885.2009.01079.x. 7. Butwan, M., Benjamin, R.L. & Bloomer, R.J., 2017. Methylsulfonylmethane:
applications and safety of a novel dietary supplement. Nutrients, 9:290. doi:10.3390/nu9030290. 8. Oesser, S. & Seifert, J., 2003. Stimulation of type II collagen biosynthesis and secretion in bovine chondrocytes
cultured in degraded collagen. Cell and Tissue Research, 311:393-399. doi:101007/s0441-003-0702-8. 9. Vasiliadis, H.S. & Tsikopoulos, K., 2017. Glucosamine and chondroitin for the treatment of osteoarthritis.
World Journal of Orthopopedics, 8(1):1-11. doi:10.5312/wjo.v8.i1.1. 10. Martel-Pelletier, J., Farran, A., Montell, E., Verges, J. & Pelletier, J., 2015. Discrepancies in composition and biological effects of different
formulation of chondroitin sulfate. Molecules, 20:4277-4289. doi:103390/molecules20034277. 11. Wang, S.X., Laverty, S., Dumitriu, M., Plaas, A. & Grynpas, D., 2007. The effects of glucosamine hydrochloride on
subchondral bone changes in an animal model of osteoarthritis. Arthritis & Rheumatism, 56(5):1537-1548. doi:10.1002/art.22574. 12. Schlueter, A.E. & Orth, M.W., 2004. Equine osteoarthritis: a brief review of the
disease and its causes. Equine and Comparative Exercise Physiology, 1(4):221-231. doi:10.1079/ECEP200428. 13. Pearson, W. & Lindinger, M., 2008, Critical review of research evaluating glucosamine-based
nutraceuticals for treatment of joint pain and degenerative joint disease in horses. Wageningen University and Research Centre, 81-91.

bottom of page